Video

Dr. Primo Lara on the need for multidisciplinary care in kidney cancer

Author(s):

Urology Times staff

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Dr. Primo Lara, Jr., executive associate dean for Cancer Programs, School of Medicine, at UC Davis Comprehensive Cancer Center, highlights the need for personalized medicine using multidisciplinary care for patients with renal cell carcinoma.

      Newsletter

      Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

      Subscribe Now!
      Related Videos
      Doctor consulting patient | Image Credit: © Liudmila Dutko - stock.adobe.com
      Strategies to bridge gender disparities in AAS and citations in the oncology literature
      Jad Chahoud, MD, on first-line zanzalintinib plus nivolumab for advanced ccRCC
      Jad Chahoud, MD, on first-line zanzalintinib plus nivolumab for advanced ccRCC
      Female doctor typing on her laptop computer in medical office | Image Credit: © Rostislav Sedlacek - stock.adobe.com
      Study findings highlight gender gaps in oncology authorship and citation
      Rebecca A. Campbell, MD, answers a question during a Zoom video interview
      Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
      Study data point to gender disparities in oncology research citations
      Study data point to gender disparities in oncology research citations
      Nitin Yerram, MD, highlights new resource center for patients with renal cell carcinoma
      Nitin Yerram, MD, highlights new resource center for patients with renal cell carcinoma
      Betty Wang, MD, discusses studies from the 2025 EAU meeting
      Betty Wang, MD, recaps 3 key urologic cancer studies from EAU 2025
      Darren Feldman, MD, on study of 177Lu-girentuximab plus nivolumab for ccRCC
      Darren Feldman, MD, on study of 177Lu-girentuximab plus nivolumab for ccRCC
      Francesca Jackson-Spence, MBChB, details the ongoing SAMETA trial in papillary renal cancer
      Francesca Jackson-Spence, MBChB, details the ongoing SAMETA trial in papillary renal cancer
      Kate Gessner, MD, on systemic agents vs MDT after kidney cancer progression
      Kate Gessner, MD, on systemic agents vs MDT after kidney cancer progression
      Related Content
      What urologists can expect in Q3 of 2025
      June 30th 2025

      What urologists can expect in Q3 of 2025

      Benjamin P. Saylor Hannah Clarke
      A comprehensive guide to the key regulatory decisions and conferences slated for Q3 of 2025.
      3d rendered medically accurate illustration of kidney cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
      June 6th 2025

      Pivotal trial of histotripsy system for kidney tumors reaches enrollment goal

      Hannah Clarke
      Data from the #HOPE4KIDNEY trial is intended to support submission for regulatory clearance of the Edison Histotripsy System.
      Human kidney cross section on scientific background | Image Credit: © Crystal light - stock.adobe.com
      June 5th 2025

      Sintilimab plus fruquintinib under review in China for advanced renal cell carcinoma

      Hannah Clarke
      The new drug application is backed by data from the phase 2/3 FRUSICA-2 trial.
      Jad Chahoud, MD, MPH
      June 5th 2025

      Zanzalintinib plus nivolumab shows safety, efficacy for stage 4 RCC

      Benjamin P. Saylor
      ORR in the zanzalintinib plus nivolumab arm was 63% (95% CI: 46-77) vs 40% (95% CI: 25-57) in the zanzalintinib plus nivolumab/relatlimab arm.
      Medically accurate illustration of kidney cancer | Image Credit: © Crystal light - stock.adobe.com
      June 1st 2025

      Adjuvant pembrolizumab continues to show DFS, OS benefits for ccRCC at 5-year assessment

      Silas Inman
      "These long-term results continue to support [pembrolizumab's] use as a standard of care for patients at increased risk of recurrence," says Naomi B. Haas, MD.
      Subcutaneous nivolumab approved in EU, Canada for solid tumors
      May 28th 2025

      Subcutaneous nivolumab approved in EU, Canada for solid tumors

      Hannah Clarke
      The approvals are supported by findings from the phase 3 CheckMate-67T trial.
      © 2025 MJH Life Sciences

      All rights reserved.